From Deseret News archives:
Clinical trials are driven by hope
But studies are complex, face ethical, safety issues
Further study called in question the drug's mechanism. It seems a side effect was severe gastric distress and raging diarrhea. Further study showed people who had experienced the side effect, even once, simply chose to avoid food at all costs whenever possible.
In a mid-'70s trial of a cholesterol-lowering drug, the NIH sponsors found that participant side effects varied from one study site to another. It turned out it depended on the order the side effects were listed on the consent form. "If constipation was listed first, that's what you got," Ferguson said.
To the finish line
Avastin has become a frontline treatment for colorectal cancer patients, according to its Web site. Even the earliest study data suggested those who received it lived about four months longer than patients on chemotherapy alone. The drug blocks new vessels and thus tumor growth, said Dr. Graydon Harker, president of Utah Cancer Specialists. The trial looked at whether it, combined with chemotherapy, works better than either one alone.
Harker said he's seen some very dramatic results during clinical trials. "Probably better than I had hoped for."
Like all clinical study medications, there are potential problems. Avastin was no exception. Since tumors need new blood vessels to grow, shutting down their development would likely hurt the cancer. But the body needs new blood vessels for tissues that are regenerating, including bone marrow and muscle. There's a risk that needed vessel development could be thwarted. And the list of potential, unknown complications during the trial included concerns about stroke, kidney problems and even contradictory complications, bleeding and clotting.
There were questions besides simple effectiveness, too. Is the drug or the combination more toxic? Does it cause more mouth problems, sores, nausea, vomiting, diarrhea?
Downside with an upside
One downside to clinical trials is patients may not get new medication that could help them. Some receive a placebo.
Still, that's a powerful tool. Doctors know all about the "placebo effect," amazing responses by those receiving nothing more potent than sugar, based on the belief they're getting the study drug.
Comments
- Oden hurt, done for season? 12:56 a.m.
- USU home-court streak ends 12:55 a.m.
- USU names field after Merlin Olsen 12:52 a.m.
- Utes stop Idaho State 12:51 a.m.
- Y., U. to learn bowl destinations 12:49 a.m.
- Utes' team staying well-tuned 12:48 a.m.
- Kirilenko sits, Miles improves 12:47 a.m.
- BYU basketball: Cougars crush Dons 12:38 a.m.
- Kirilenko will not play tonight 12:34 a.m.
- Surprise job comeback 12:33 a.m.
- Why is Y. ignoring spew of hatred?
309 - Letters: Liberal because LDS
247 - Y. profs: Beck not all-knowing
195 - Hate not limited to 1 in-state rivalry
189 - Aggies shoot past Cougars
179 - N.Y. Senate rejects gay marriage
128 - Unbeaten BYU takes trip to Logan
105 - George lost in rivalry hatefest
104 - Harpring's NBA career is over
94 - Ed Smart 'appalled' at testimony
90
Trolley Square's annual Holiday Open House will feature visits with...
That does it — I'm having an affair! Thanks to Tiger Woods, David...
First, a big thank you to all who posted questions here for me to ask...
We'll be watching the AGGIES in the NIT. At least BYU will BE in the NCAA....
You're right, the REFs don't care...they laugh when they leave the...
Las Vegas- Wyoming v USC Poinsettia- Air Force v Cal Armed Forces- Utah v....
Just another mental lapse. This is the NBA, this isn't a regular high school...
T-Buck, ESPN's box has CJ Miles shooting 3-for-10. Not a great deal of...
Tiger Woods used the media build up and sponsorship $$$ to attract...
Hey fellow Aggies, quit whining. We lost to the better team tonight. BYU...
I am glad the Cougars won this one too. What was the score with AZ...
More Maynor, 10 min. of Fes, we get the win. Since Jerry's extension, Fes...
Ivan--thank you buddy. It's always good to get the input of a BYU fine...




You can be the first to comment on this story.